Drug news
NICE rejects Onivyde as a cost effective treatment for metastatic adenocarcinoma of the pancreas. - Shire plc
The National Institute for Health and Care Excellence (NICE) has issued draft guidance rejecting Onivyde (nanoliposomal encapsulated irinotecan) from Shire plc as a treatment for metastatic adenocarcinoma of the pancreas after chemotherapy as the drug was not considered cost effective at £1846.05 per week for a two week cycle .Onivyde did not extend survival for long enough to qualify for its end of life criteria.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins